Health
Emyria and partner Mind Medicine Australia launch psychedelic-assisted therapy program targeting PTSD – Proactive Investors Australia
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS). Emyria Ltd (ASX:EMD) and partner Mind Medicine Australia have launched the EMDMA-001 psychedelic-assisted therapy program targeting sufferers of treatment-resistant post-traumatic stress disorder (PTSD).
As a first step, and pending ethics approval, Emyria, an innovative drug development and clinical services company, will sponsor a major, independently monitored,…
-
General18 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News22 hours agoBrisbane rising on global rankings, but still behind southern capitals
-
General18 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News9 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones